沙利鲁单抗
| 单克隆抗体 | |
|---|---|
| 种类 | 完整抗体 |
| 目标 | IL-6R |
| 临床资料 | |
| 商品名 | Kevzara |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a617032 |
| 核准状况 | |
| 给药途径 | 皮下注射 |
| ATC码 | |
| 法律规范状态 | |
| 法律规范 |
|
| 药物动力学数据 | |
| 生物利用度 | 80% |
| 药物代谢 | 可能是由蛋白酶 |
| 生物半衰期 | 21 天（预估，稳定态） |
| 识别信息 | |
| CAS号 | 1189541-98-7  |
| ChemSpider |
|
| UNII | |
| KEGG | |
| 化学信息 | |
| 化学式 | C6388H9918N1718O1998S44 |
| 摩尔质量 | 144,164.28 g·mol−1 |
沙利鲁单抗（INN：Sarilumab）是治疗类风湿性关节炎的药物[5]。用于治疗传统治疗无效的中度至重度疾病[5]。若无法取得托珠单抗时，也能用于治疗重症2019冠状病毒病 [6]。透过皮下注射给药[5]。
最常见的副作用是感染[7]。其他副作用可能包括嗜中性白血球低下、血小板减少症、血脂异常、肝脏问题、过敏和癌症[7] [8]。注射部位可能会疼痛[5]。它是一种单克隆抗体，可与白细胞介素-6受体结合并阻断其功能[5]。
沙利鲁单抗于 2017 年在美国和欧洲取得医疗使用取可[8] [5]。
参考文献
[编辑]- ^ Arthritis. Health Canada. 8 May 2018 [13 April 2024].
- ^ Regulatory Decision Summary for Kevzara. Drug and Health Products Portal. 12 January 2017 [13 April 2024].
- ^ Kevzara- sarilumab injection, solution. DailyMed. 17 June 2024 [26 August 2024].
- ^ Kevzara EPAR. European Medicines Agency (EMA). 23 June 2017 [26 August 2024].
- ^ 5.0 5.1 5.2 5.3 5.4 5.5 Kevzara. [11 October 2021]. （原始内容存档于13 September 2021）.
- ^ Clinical Management Summary. COVID-19 Treatment Guidelines. [19 January 2022]. （原始内容存档于5 November 2021） （英语）.
- ^ 7.0 7.1 Shagroni, T.; Cazares, Ramirez; Kim, J. A.; Furst, Daniel E. Katzung, Bertram G.; Trevor, Anthony J. , 编. 36. Nonsteroidal anti-inflammatory drugs, disease-modifying antirheumatic drugs, nonopioid analgesics, & drugs used in gout 15th. New York: McGraw-Hill. 2020: 678 [2021-11-06]. ISBN 978-1-260-45231-0. （原始内容存档于2021-10-10） （英语）.
- ^ 8.0 8.1 Sarilumab Monograph for Professionals. Drugs.com. [11 October 2021]. （原始内容存档于17 April 2021） （英语）.
延伸阅读
[编辑]- Bermejo I, Ren S, Simpson E, Clowes M, Scott DL, Young A, Stevenson M. Sarilumab for Previously-Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal (PDF). PharmacoEconomics. June 2018, 36 (12): 1427–1437. PMID 29882210. S2CID 46969760. doi:10.1007/s40273-018-0677-7.
- Genovese MC, van Adelsberg J, Fan C, Graham NM, van Hoogstraten H, Parrino J, Mangan EK, Spindler A, Huizinga TW, van der Heijde D. Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes. Rheumatology. August 2018, 57 (8): 1423–1431. PMC 6055572
. PMID 29746672. doi:10.1093/rheumatology/key121. - McCarty D, Robinson A. Efficacy and safety of sarilumab in patients with active rheumatoid arthritis. Therapeutic Advances in Musculoskeletal Disease. March 2018, 10 (3): 61–67. PMC 5802641 . PMID 29492111. doi:10.1177/1759720X17752037.
- Raimondo MG, Biggioggero M, Crotti C, Becciolini A, Favalli EG. Profile of sarilumab and its potential in the treatment of rheumatoid arthritis. Drug Design, Development and Therapy. 2017, 11: 1593–1603. PMC 5447699 . PMID 28579757. doi:10.2147/DDDT.S100302 .
